BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 12, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

March 22, 2018

View Archived Issues

First patient treated in phase I study of anti-CD47 monoclonal antibody SRF-231

Read More

Eli Lilly discovers novel PDE1 inhibitors

Read More

Novel serine protease HTRA1 inhibitors identified at Roche

Read More

Genentech and Roche present new HsNIK inhibitors

Read More

Technical University of Denmark presents ROS-activated methotrexate and aminopterin prodrugs

Read More

GlaxoSmithKline divulges novel bromodomain and extra-terminal protein inhibitors

Read More

DHX34 expression predicts poor survival in melanoma patients

Read More

SAR-191801, an orally active inhibitor of H-PGDS for asthma and COPD

Read More

Cosmo Pharmaceuticals submits NDA to the FDA or rifamycin SV MMX

Read More

First patient dosed in phase II psoriasis trial of ABY-035

Read More

Eiger BioPharmaceuticals receives FDA guidance for lornafarnib HDV development

Read More

Biodesix to collaborate with Checkmate Pharmaceuticals on treatment biomarkers

Read More

Researchers discover novel phyllanthusmin analog PHY-34

Read More

FDA grants fast track designation to Pedmark

Read More

Inhaled JAK1 inhibitors synthesized for treating asthma

Read More

Helix BioPharma and ProMab Biotechnologies to collaborate on CAR-T therapy

Read More

Swedish Orphan Biovitrum launches Ravicti in Europe

Read More

Boston Scientific to acquire NxThera

Read More

AOBiome Therapeutics' ammonia oxidizing bacteria product well tolerated in phase I study

Read More

New gene fusions detected in pleomorphic adenoma

Read More

Merus and Vall d'Hebron Institute of Oncology expand collaboration

Read More

Deinove enters option and license agreement for Redx's anti-infective program

Read More

Innate Biologics to develop recombinant protein platform with the Wistar Institute

Read More

Novartis signs licensing agreement for Harvard's biomaterial-based cancer immunotherapies

Read More

LSZ-102, a potent SERD showing good oral bioavailability and clinical safety

Read More

Bayer's acquisition of Monsanto gets conditional approval in Europe

Read More

Allysta initiates phase I/II study of H-1337 for elevated intraocular pressure

Read More

Bristol-Myers Squibb studies BMS-986258 alone and with nivolumab in advanced solid tumors

Read More

GlaxoSmithKline initiates first-in-human study of GSK-3358699

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 12, 2025.
  • Illustration of SCAN in Parkinson’s vs healthy subcortex

    SCAN is core circuit affected in Parkinson’s disease

    BioWorld Science
    Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
  • Woman and 3D brain

    Astellas’ ASP-2246 shows promise in stroke management

    BioWorld Science
    Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for Feb. 10, 2026
  • 3D illustration of skin layers

    TL1A is overexpressed in hidradenitis suppurativa

    BioWorld Science
    Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing